Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering From Acute Decompensated Heart Failure [TRUE-AHF]

NCT01661634 is registered in ClinicalTrials.gov with Cardiorentis as lead sponsor.

NCT NCT01661634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01661634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ularitide (Urodilatin) Intravenous Infusion in Patients Suffering From Acute Decompensated Heart Failure [TRUE-AHF]
Lead sponsor
Cardiorentis
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2012
Completion date
March 31, 2016
Enrollment
2,157 (actual)
Sites
163

Conditions

As the registry lists them; a condition with its own page is linked.

acute decompensated heart failure